Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 26;22(1):5.
doi: 10.1007/s11864-020-00804-1.

The Benefits of Olanzapine in Palliating Symptoms

Mellar P Davis  1 , Gareth J Sanger  2
Affiliations
Review

The Benefits of Olanzapine in Palliating Symptoms

Mellar P Davis et al. Curr Treat Options Oncol. .

Abstract

Olanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. In addition, a recent randomized trial has demonstrated its benefits in treating nausea and vomiting associated with advanced cancer. The added benefit to olanzapine is that it also stimulates appetite. As a result, since it treats multiple symptoms associated with advanced cancer, it is likely to become the antiemetic of choice in palliative care at least in the USA. The added benefit of treating insomnia and the avoidance of benzodiazepines should place olanzapine in at the top of the list of drugs to use for patients who do complain of insomnia. There is no good evidence that it potentiates the respiratory depression of opioids unlike benzodiazepines. The evidence is weak that olanzapine in as an adjuvant analgesic. Hopefully, future trials will explore this in greater depth. The benefits of adding olanzapine to potent opioids are that it may reduce craving, drug cues, and opioid misuse. Other symptoms like anxiety and depression may be addressed by the addition of olanzapine to standard antidepressants.

Keywords: Advanced cancer; Appetite; Nausea; Olanzapine; Substance abuse; Vomiting.

PubMed Disclaimer

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer. 2006;14(5):444–53. - PubMed - DOI - PMC
    1. Harder S, Herrstedt J, Isaksen J, Neergaard MA, Frandsen K, Sigaard J, et al. The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. Support Care Cancer. 2019;27(8):3071–80. - PubMed - DOI - PMC
    1. Wickham RJ. Nausea and vomiting: a palliative care imperative. Curr Oncol Rep. 2020;22(1):1. - PubMed - DOI - PMC
    1. • Sanger GJ, Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front Pharmacol. 2018;9:913. https://doi.org/10.3389/fphar.2018.00913 This is a wonderful review on antiemetics which has clinical implications. This is the first author’s recommendation as an important paper to read. - DOI - PubMed - PMC
    1. • Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95 This paper helped to define cancer cachexia. - PubMed - DOI - PMC

Publication types

MeSH terms

LinkOut - more resources